- Home
- KREF vs TNGX Comparison
KREF vs TNGX Comparison
Compare KREF & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KREF
- TNGX
- Stock Information
- Founded
- KREF 2014
- TNGX 2014
- Country
- KREF United States
- TNGX United States
- Employees
- KREF N/A
- TNGX N/A
- Industry
- KREF Real Estate Investment Trusts
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- KREF Real Estate
- TNGX Health Care
- Exchange
- KREF Nasdaq
- TNGX Nasdaq
- Market Cap
- KREF 623.9M
- TNGX 723.2M
- IPO Year
- KREF 2017
- TNGX N/A
- Fundamental
- Price
- KREF $8.67
- TNGX $7.34
- Analyst Decision
- KREF Buy
- TNGX Strong Buy
- Analyst Count
- KREF 6
- TNGX 6
- Target Price
- KREF $12.04
- TNGX $10.00
- AVG Volume (30 Days)
- KREF 854.1K
- TNGX 2.6M
- Earning Date
- KREF 10-22-2025
- TNGX 11-05-2025
- Dividend Yield
- KREF 11.49%
- TNGX N/A
- EPS Growth
- KREF N/A
- TNGX N/A
- EPS
- KREF N/A
- TNGX N/A
- Revenue
- KREF $40,393,000.00
- TNGX $24,296,000.00
- Revenue This Year
- KREF $23.74
- TNGX $20.42
- Revenue Next Year
- KREF N/A
- TNGX N/A
- P/E Ratio
- KREF N/A
- TNGX N/A
- Revenue Growth
- KREF N/A
- TNGX N/A
- 52 Week Low
- KREF $8.28
- TNGX $1.03
- 52 Week High
- KREF $12.33
- TNGX $8.80
- Technical
- Relative Strength Index (RSI)
- KREF 29.44
- TNGX 48.40
- Support Level
- KREF $8.87
- TNGX $7.66
- Resistance Level
- KREF $9.13
- TNGX $8.80
- Average True Range (ATR)
- KREF 0.20
- TNGX 0.48
- MACD
- KREF -0.09
- TNGX -0.07
- Stochastic Oscillator
- KREF 5.73
- TNGX 21.47
About KREF KKR Real Estate Finance Trust Inc.
KKR Real Estate Finance Trust Inc is a real estate finance company that focuses on originating and acquiring senior mortgage loans secured by CRE assets. The investment is to originate or acquire senior mortgage loans collateralized by institutional-quality CRE assets that are owned and operated by experienced and well-capitalized sponsors and located in liquid markets with underlying fundamentals. KKR manages investments across multiple asset classes, including private equity, real estates, energy, infrastructure, credit, and hedge funds. The company's investment objective is capital preservation and generating attractive risk-adjusted returns for its stockholders over the long term, through dividends.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.